Medindia LOGIN REGISTER
Medindia
Advertisement

Legal Cannabis Market Gaining Traction

Wednesday, March 8, 2017 Drug News
Advertisement
NEW YORK, March 8, 2017 /PRNewswire/ --
Advertisement

The global medical marijuana market is expected to reach a value of USD 55.8 billion by 2025, according to a new report by Grand View Research, Inc., the report indicates that together with Washington D.C. 28 states have legalized marijuana for medical uses. In 2016, states such as Arkansas, Florida, North Dakota, Ohio, and Pennsylvania were approved to use the drug in medical applications such as chemotherapies and pain management. The growing number of states and countries getting approval for using it in therapeutic applications is one of the crucial factors driving the demand over the coming few years. In addition, successful legalization for recreational use in states like California. ChineseInvestors.com (OTC: CIIX), Cannabis Sativa Inc. (OTC: CBDS), Eco Science Solutions Inc. (OTC: ESSI), Vitality Biopharma Inc. (OTC: VBIO), CV Sciences Inc. (OTC: CVSI).
Advertisement

Florida by itself is projected to become a major market after voters overwhelmingly chose to legalize medical marijuana with more than 70% of the vote. According to Arcview Market Research, the potential growth of the medical market in Florida is strong. The market is projected to reach $1.6 billion by 2020, growing at a compound annual growth rate of 140%. "The opportunity for good jobs, tax money and wealth creation created by Amendment 2 passing cannot be understated. Savvy entrepreneurs and pioneering investors are rightfully exuberant about the Florida market. And, thankfully, seriously ill patients will no longer need to go to high school parking lots or drug dealers to get their medicine," said Troy Dayton, CEO of The Arcview Group.

ChineseInvestors.com (OTCQB: CIIX) announced earlier in February that, "The launch of its new website for its new subsidiary ChineseCBDoil.com. The website went live on January 31st under the URL: http://www.ChineseCBDoil.com . The Company is expanding into the medical marijuana industry with the launch of its website and plans to retail hemp oil and related products, which are legal to sell and distribute within China and in the United States in all fifty states (hemp oil is not marijuana, but indeed a separate and distinct plant made from hemp). CBD oil, derived from hemp is a product with medicinal qualities that are primarily used for anti-inflammatory and other common ailments. Its website is intended for the Chinese speaking population, a global market of 2 Billion people." 

Our expertise in online communications with our background in media, technology, and journalism, via our http://www.Chinesefn.com website will further enhance our success. Our core business, the online distribution of news to the Chinese speaking population about financial markets and stocks has been a very solid and consistently robust business for our shareholders. Now as we expand into online retailing and distribution of CBD oils to the Chinese speaking population with a focus on hemp and medicinal needs via consumer products. This will create a much needed and growing niche for us to enter. Indeed, we believe we are the first public company to enter this market in China." In addition, earlier this week, SeeThruEquity announced it has issued an update note on ChineseInvestors.com, giving the company a price target to $3.75.

Cannabis Sativa Inc. (OTCQB: CBDS) announced that its new Ibudtender app will be ready for beta testing. The app will hold the highest health and safety standards for consumers to date. "The Ibudtender team has been working hard to complete what will be the most sophisticated app in the space", said David Tobias, President of Cannabis Sativa. "The beta test will give the technology a chance to perform, interact with users, get analyzed and perfected, and a final release to follow quickly." Ibudtender is accepting applications from select consumers for this project. Ibudtender is also accepting a limited number of dispensaries, delivery services and manufacturers to test its new state of the art business software.

Eco Science Solutions Inc. (OTCQB: ESSI) owns the application, Herbo. Herbo are growers, users, and beneficiaries of cannabis. The app was made to help users find medical cannabis dispensaries, smoke shops, legal doctors, clinics, and delivery services in specific areas, but also wants to help users ingest cannabis the best possible ways. So they partnered with the largest and best paraphernalia manufacturers and distributors to bring awesome products at great prices.

Vitality Biopharma Inc. (OTCQB: VBIO) announced the company had recreated a library of proprietary glycosides of THC, the main psychoactive chemical found in cannabis or marijuana, which enable targeted delivery that reduces or eliminates psychoactivity when used in oral drug formulations. These compounds are being developed as pharmaceuticals that enable site-specific targeting of the THC in various tissues of the body, where it can exert therapeutic effects for treatment of pain and inflammation. Recently, the company gained DEA approval for its research and development facilities located in California, and it has now completed preclinical pharmacokinetics studies with its proprietary THC glycosides to analyze their bioavailability. The Company has confirmed that large concentrations can be delivered orally without significant transit of THC to the brain, enabling their formulation within pharmaceuticals where drug psychoactivity will be reduced or eliminated.

CV Sciences Inc. (OTCQB: CVSI), focuses on drug development activities on products containing cannabidiol (CBD) as the active pharmaceutical ingredient, and also is engaged in the sale of CBD, and the development, marketing and sale of end consumer products containing CBD, which is refined into its own PlusCBD Oil™ brand, the leading hemp-derived CBD product line in the United States. The company will be exhibiting its PlusCBD Oil™ at Natural Products Expo West in mid-March. As the preeminent leaders in hemp-derived CBD, we believe it is our obligation to create products that retailers can count on," stated Stuart Tomc, VP of Human Nutrition and spokesperson at CV Sciences. "PlusCBD Oil™ has been driving the growth of this newly emerging category due to the consistency, efficacy, and safety profile of our products. We are pleased to report that PlusCBD Oil™ is now available in over 1000 health food stores and counting, and we truly have our retailer partners to thank for joining the CBD Evolution -- many of whom have been with us since our first Expo West two years ago."

Please SIGN UP NOW at http://www.FinancialBuzz.com to Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook - Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com  

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions or commentary. FinancialBuzz.com expects to be compensated five thousand dollars for financial news dissemination and pr services by chineseInvestors.com inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed a two year agreement with chineseinvestors.com inc. for one hundred thousand restricted common shares for continued financial news dissemination and pr services. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information: Media Contact: [email protected] +1-877-601-1879

URL: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com

Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close